Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC

NCT04174781 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

61

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Sintilimab
DRUG: DEB-TACE

Sponsor

Zhejiang University